Almotriptan (Axert) vs Rizatriptan (Maxalt)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: 5-HT1B/1D receptor · full Migraine pipeline

Almotriptan (Axert)

Rights held by Almirall and partners

US approval withdrawn in Migrainesmall molecule
Weak signal

NCT00257010 · Phase 3 · completed

This was a single-group, open-label study with 447 enrolled participants and no placebo or active comparator, so the reported pain-free headache counts cannot establish how much benefit was caused by almotriptan. The primary endpoint was a clinical migraine outcome, but no between-group comparison or statistical test was possible.

No aligned efficacy figure on record for this race.

Rizatriptan (Maxalt)

Marketed by Organon

Approved in Migrainesmall molecule
Partial signal

NCT00897949 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial, and both rizatriptan doses significantly increased pain relief at 2 hours compared with placebo. The sources available for this trial do not report a sample-size calculation or a planned enrolment, so it cannot be confirmed that the trial was adequately powered.

Reported efficacy

Pain Relief at 2 Hours After the Initial Dose of Test Drug (2 hours after initial dose of test drug): Pain relief at 2 hours after the first dose: rizatriptan 5 mg 62% (285/457) and 10 mg 71% (322/455) vs placebo 35% (106/302), significantly higher for both doses (Teall et al., Headache 1998; CT.gov posted counts). (met)

Result source: NCT00897949

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Almotriptan (Axert): registry results are on file for Migraine, but their comparison mappings are not yet available.

Rizatriptan (Maxalt): registry results are on file for Migraine, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Almotriptan (Axert)'s landscape · Rizatriptan (Maxalt)'s landscape